NOVAVAX INC [NVAX] reports annual net loss of $545,062,000.0
Company Reports Revenue of $983.7 million
NOVAVAX INC[NVAX] has reported a net loss of $545,062,000.0 for year ended Dec 31, 2023.
The Company said in a filing before the Securities and Exchange Commission that its total revenue for the year was $983.7 million
Based in GAITHERSBURG, Maryland, NOVAVAX INC operates in the MANUFACTURING sector.
In the 12 months that ended on December 31, 2023, the consolidated revenue totaled $983.7 million. This reflects a decrease from the previous year's revenue of $1,981.9 million. In comparison to the revenue reported in December 31, 2021, which amounted to $1,146.3 million, the current year's revenue also decreased.
Moving on to expenses, the cost of sales for the current period stood at $343.8 million. This represents a decrease from the previous year's cost of sales, which amounted to $902.6 million. Notably, there were no reported cost of sales for the period ending December 31, 2021.
Furthermore, the net loss for the 12 months ending on December 31, 2023, amounted to $(545.1) million. This signifies an improvement compared to the net loss of $(657.9) million reported in the previous year. In the same comparison, the net loss in December 31, 2021, was $(1,743.8) million.
Additionally, the basic and diluted net loss per share for the current period were both reported at $(5.41) per share. This figure has improved from the previous year's basic and diluted net loss per share of $(8.42) and the period ending December 31, 2021, which was $(23.44) per share.
The weighted average number of common shares outstanding for both basic and diluted calculations are consistent across all three reported periods.
USInMinutes/IndiaInMinutes is an offering of 10kInfo, Inc., bringing you news on the latest regulatory filings. You may subscribe to more news alerts here. Although care is taken to ensure accuracy of the data, the article does not intend to replace user diligence while taking decisions of financial or legal implications